Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amherst Sour Diesel is a Sativa-dominant cannabis cultivar developed by the Humboldt Seed Organization, resulting from a genetic cross between Chemdawg and Amherst Super Skunk. It is characterized by a high concentration of delta-9-tetrahydrocannabinol (THC), often ranging between 20% and 27%, and a complex terpene profile that includes limonene, myrcene, and caryophyllene. The strain is widely utilized in medical cannabis programs for its reported uplifting and energizing effects, making it a common choice for patients managing chronic stress, clinical depression, and physical fatigue. Its primary mechanism of action involves the interaction of phytocannabinoids with the human endocannabinoid system, specifically acting as an agonist at the CB1 and CB2 receptors to modulate neurotransmitter release and physiological responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amherst Sour Diesel.